The Pulmonary Hypertension Association marks November as its Pulmonary Hypertension (PH) awareness month. Awareness of rare and life-threatening diseases, such as PH, may lead to a higher survival rate for these patients in future years, and progress has already been seen for PH survival statistics in the last 20 years.
Pulmonary Hypertension (PH) occurs when the patient’s pulmonary artery walls become stiff and thickened, it is more difficult for the heart to pump blood through these arteries, and the pressure therefore increases inside them. The reason for such changes are multiple and therefore pulmonary hypertension is classified into different types depending on the underlying cause: pulmonary arterial hypertension (PAH), PH associated with left heart disease, PH associated with lung disease and hypoxia, chronic thromboembolic pulmonary hypertension (CTEPH) and PH due to other causes. We have further characterised the eligible patient population by associated patient attributes and co-morbid conditions, such as COPD, fibrotic diseases, cardiovascular diseases and diabetes mellitus. Consequently, this generated 180 different sub-populations for this disease.
In many types of PH the underlying cause has to be treated first, but with PAH the arteries are affected directly and it can therefore be treated immediately. This is a rare disease but is a niche that holds potential and much unmet need. In the Epiomic™ Database, the aetiology for PAH has been thoroughly segmented by associated congenital heart disease, connective tissue disease, drug induced, idiopathic, portal hypertension and PPHN.
This is a complex disease due to the involvement of many different factors. For further information on PH or any of our other EpiomicTMdatabase diseases/bespoke services please contact us via the details provided.